OncRef

Clinical Trial: NCT03899792

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Eli Lilly and Company
Information Provided By:Eli Lilly and Company
Last Update Posted:2026-01-06

Study Overview

Brief Summary

This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.

Official Title

A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Conditions

Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma

Intervention / Treatment

  • Drug: Selpercatinib

Other Study ID Numbers

  • 17493
  • J2G-OX-JZJJ
  • LOXO-RET-18036
  • 2019-000212-28
  • 2019

Start Date (Actual)

2019-06-13

Primary Completion Date (Actual)

2024-11-08

Study Completion Date (Estimated)

2029-05

Enrollment (Actual)

36

Study Type

Interventional

Phase

Phase 1, Phase 2